Depemokimab demonstrates efficacy in patients with type 2 asthma with comorbid CRSwNP: Phase III SWIFT-1/-2 analysis - PubMed
6 hours ago
- #CRSwNP
- #biologics
- #asthma
- Depemokimab showed efficacy in patients with type 2 asthma and comorbid CRSwNP in Phase III SWIFT-1/-2 trials.
- The study involved patients receiving depemokimab 100 mg or placebo every 26 weeks for 52 weeks.
- Depemokimab significantly reduced annualized exacerbation rates compared to placebo in the CRSwNP subgroup.
- Improvements in SGRQ and ACQ-5 scores were noted early and sustained up to 52 weeks with depemokimab.
- The benefits of depemokimab were greater in the CRSwNP subgroup than in the overall study population.
- The findings suggest that depemokimab is particularly beneficial for type 2 asthma patients with CRSwNP.